Contact Us
Drug Search Results
More Filters [+]

PB-1023

Alternative Names: pb-1023, pb1023, pb 1023
Latest Update: 2020-09-15
Latest Update Note: News Article

Product Description

a long-acting, recombinant GLP-1 analogue for the treatment of certain diseases, including conditions related to sarcopenia. PB1023 was created as a genetic fusion protein utilizing PhaseBioÕs proprietary elastin-like polypeptide (ÒELPÓ) technology platform. (Sourced from: https://investors.phasebio.com/news-releases/news-release-details/phasebio-announces-global-license-pb1023-treatment-sarcopenia)

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: PhaseBio
Company Location: MALVERN PA 19355
Company CEO: Jonathan P. Mow
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PB-1023

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Phase 1: Type 2 Diabetes|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PB1023-PT-CL-0004

P2

Completed

Type 2 Diabetes

2013-07-01

PB1023-PT-CL-0003

P1

Completed

Kidney Diseases|Type 2 Diabetes

2012-10-01

PB1023-PT-CL-0002

P1

Completed

Type 2 Diabetes

2012-09-01

PB1023-PT-CL-0001

P2

Completed

Type 2 Diabetes

2011-11-01

Recent News Events

Date

Type

Title

09/15/2020

News Article

 Global Sarcopenia Market Insights, Epidemiology and Forecasts, 2017-2019 & 2020-2030 - BIO101 (Biophytis) and Bimagrumab (Novartis) are the Major Players - ResearchAndMarkets.com

04/09/2019

News Article

 PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions